MEDICAMEQPharmaceuticals
Medicamen Biotech Ltd — Cash Flow Statement
₹223.30
-4.88%
Medicamen Biotech Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | -9.27 Cr | -13.03 Cr | -12.89 Cr | -4.50 Cr | — |
| Repayment Of Debt | -0.04 Cr | — | -4.20 Cr | -1.33 Cr | — |
| Issuance Of Debt | 1.67 Cr | 6.63 Cr | 4.04 Cr | 8.35 Cr | — |
| Issuance Of Capital Stock | 0.86 Cr | 1.90 Cr | 33.41 Cr | 0.00 | — |
| Capital Expenditure | -2.07 Cr | -6.29 Cr | -6.60 Cr | -8.61 Cr | — |
| End Cash Position | 3.75 Cr | 14.79 Cr | 20.78 Cr | 3.82 Cr | — |
| Beginning Cash Position | 14.77 Cr | 20.78 Cr | 3.82 Cr | 3.89 Cr | — |
| Changes In Cash | -11.02 Cr | -5.99 Cr | 16.95 Cr | -0.07 Cr | — |
| Financing Cash Flow | -1.94 Cr | 6.31 Cr | 29.13 Cr | 4.30 Cr | — |
| Interest Paid Cff | -3.16 Cr | -4.40 Cr | -2.92 Cr | -1.40 Cr | — |
| Cash Dividends Paid | -1.27 Cr | -1.27 Cr | -1.27 Cr | -1.22 Cr | — |
| Net Common Stock Issuance | 0.86 Cr | 1.90 Cr | 33.41 Cr | 0.00 | — |
| Common Stock Issuance | 0.86 Cr | 1.90 Cr | 33.41 Cr | 0.00 | — |
| Net Issuance Payments Of Debt | 1.62 Cr | 6.63 Cr | -0.17 Cr | 7.02 Cr | — |
| Net Short Term Debt Issuance | -0.04 Cr | 6.25 Cr | 4.04 Cr | 8.35 Cr | — |
| Short Term Debt Payments | -0.04 Cr | — | — | — | — |
| Net Long Term Debt Issuance | 1.67 Cr | 0.39 Cr | -4.20 Cr | -1.33 Cr | — |
| Long Term Debt Issuance | 1.67 Cr | 0.39 Cr | — | — | 4.05 Cr |
| Investing Cash Flow | -1.89 Cr | -5.56 Cr | -5.88 Cr | -8.47 Cr | — |
| Interest Received Cfi | 0.49 Cr | 0.72 Cr | 0.72 Cr | 0.14 Cr | — |
| Net Investment Purchase And Sale | -0.30 Cr | 0.00 | 0.00 | 0.00 | — |
| Purchase Of Investment | -0.30 Cr | 0.00 | 0.00 | 0.00 | — |
| Net PPE Purchase And Sale | -2.07 Cr | -6.29 Cr | -6.60 Cr | -8.61 Cr | — |
| Purchase Of PPE | -2.07 Cr | -6.29 Cr | -6.60 Cr | -8.61 Cr | — |
| Operating Cash Flow | -7.19 Cr | -6.74 Cr | -6.29 Cr | 4.11 Cr | — |
| Taxes Refund Paid | -1.35 Cr | -3.06 Cr | -3.12 Cr | -3.20 Cr | — |
| Change In Working Capital | -26.08 Cr | -27.52 Cr | -28.78 Cr | -17.82 Cr | — |
| Change In Other Current Liabilities | -9.10 Cr | 3.77 Cr | 2.26 Cr | 0.12 Cr | — |
| Change In Other Current Assets | -1.64 Cr | -17.13 Cr | -9.14 Cr | 2.28 Cr | — |
| Change In Payable | 3.80 Cr | -8.64 Cr | 4.29 Cr | 11.09 Cr | — |
| Change In Inventory | -2.76 Cr | -14.32 Cr | -18.05 Cr | -21.81 Cr | — |
| Change In Receivables | -12.32 Cr | 12.32 Cr | -3.94 Cr | -5.69 Cr | — |
| Other Non Cash Items | 2.66 Cr | 3.67 Cr | 2.20 Cr | 1.27 Cr | — |
| Deferred Tax | 3.94 Cr | 3.58 Cr | 2.32 Cr | 3.20 Cr | — |
| Depreciation And Amortization | 7.08 Cr | 7.09 Cr | 6.37 Cr | 5.77 Cr | — |
| Depreciation | 7.08 Cr | 7.09 Cr | 6.26 Cr | 5.67 Cr | — |
| Gain Loss On Sale Of PPE | 0.00 | 3000.00 | -68000.00 | -12000.00 | — |
| Net Income From Continuing Operations | 6.55 Cr | 9.49 Cr | 14.73 Cr | 14.90 Cr | — |
| Other Cash Adjustment Outside Changein Cash | — | -1000.00 | -1000.00 | — | — |
| Net Other Financing Charges | — | 3.44 Cr | 0.48 Cr | -0.10 Cr | 0.15 Cr |
| Short Term Debt Issuance | — | 6.25 Cr | 4.04 Cr | 8.35 Cr | 3.31 Cr |
| Net Other Investing Changes | — | -4000.00 | — | — | — |
| Amortization Cash Flow | — | 0.17 Cr | 0.11 Cr | 0.10 Cr | 0.06 Cr |
| Long Term Debt Payments | — | — | -4.20 Cr | -1.33 Cr | — |
| Common Stock Dividend Paid | — | — | — | — | -0.61 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Medicamen Biotech Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.